Related by context. All words. (Click for frequent words.) 65 Ph + ALL 63 chronic myeloid leukemia CML 62 Gleevec resistant 62 cytopenias 60 T#I mutation 60 metastatic malignant melanoma 60 imatinib therapy 60 malignant ascites 60 tumor necrosis 59 myeloproliferative disorder 59 nilotinib 59 paragangliomas 58 T#I [002] 58 interferon ribavirin 58 mutated KRAS 58 imatinib resistant 57 lymphoid blast 57 Chronic Myeloid Leukaemia 57 leukemia AML 57 gastrointestinal stromal tumors GIST 57 hematologic toxicity 57 cytogenetic responses 57 MCyR 57 haematologic 57 cytogenetic response 57 TNF antagonist 57 epithelial tumors 57 myeloid 56 hematological toxicity 56 VAPRISOL 56 tumor lysis syndrome 56 acute GvHD 56 relapsed AML 56 IL 1ß 56 haematological 56 chronic myelogenous leukemia CML 56 serous ovarian cancer 56 K ras mutations 56 viral reactivation 55 skeletal metastases 55 osteoclastic 55 adverse cytogenetics 55 M#V mutation 55 metastatic malignant 55 lymphocytosis 55 ara C 55 Toxicities 55 rituximab monotherapy 55 tumor regressions 55 EGFR TKI 55 riociguat 55 QT interval prolongation 55 thyroid carcinoma 55 myeloproliferative diseases 55 CCyR 55 idiopathic thrombocytopenic purpura ITP 55 corticosteroid therapy 55 complete cytogenetic response 55 parkinsonian symptoms 55 malignant neoplasms 55 HSCT 55 CML 55 hypercalcemia 55 anthracycline chemotherapy 55 noninfectious uveitis 55 pheochromocytoma 54 Gleevec imatinib mesylate 54 pancreatic carcinoma 54 cytostatic 54 neovascular 54 hepatorenal syndrome 54 invasive aspergillosis 54 metastatic lesions 54 BRAF V#E mutation 54 hepatic encephalopathy HE 54 DACH platinum 54 Bcr Abl T#I mutation 54 imatinib resistance 54 MGd 54 indolent lymphomas 54 Aplidin 54 mucinous 54 refractory AML 54 genotypic resistance 54 postoperative chemotherapy 54 GRN# 54 dexanabinol 54 scintigraphic 54 dasatinib 54 indolent NHL 54 severe hypersensitivity reactions 54 pulmonary toxicity 54 anemia neutropenia 54 recurrent glioblastoma multiforme 54 iclaprim 54 metastatic CRC 54 GISTs 54 imatinib Gleevec 54 immune thrombocytopenic purpura ITP 54 myeloproliferative disorders 54 biliary tract cancer 54 imatinib 54 AMN# [001] 54 ribavirin therapy 53 complete remissions 53 achieved CCyR 53 Ribavirin causes 53 TNF blocker therapy 53 EXJADE 53 leukaemias 53 nephrotoxic 53 infliximab therapy 53 Vojo Vukovic MD Ph.D. 53 Xanafide 53 cell lymphoma CTCL 53 cardiotoxic 53 tyrosine kinase inhibitor TKI 53 alkylating agent 53 colorectal cancer liver metastases 53 thymoma 53 perineural invasion 53 TMEM density 53 interferon therapy 53 FluCAM 53 canakinumab 53 mg kg dose 53 hA# 53 docetaxel chemotherapy 53 nucleoside analogs 53 sclerosing 53 Fludarabine 53 papillary thyroid carcinoma 53 CIMZIA ™ 53 bortezomib Velcade 53 intravenous cyclophosphamide 53 mycosis fungoides 53 circulating EPCs 53 anti leukemic 53 airway narrowing 53 SPRYCEL ® 53 virological failure 53 eculizumab therapy 53 lesional 53 mononuclear 53 myelodysplastic syndrome MDS 53 follicular lymphomas 53 ERBB2 53 virological response 53 systemic anaplastic large 53 sarcomatoid 53 NMIBC 53 malperfusion 53 tyrosine kinase inhibitors TKIs 53 Myelodysplastic Syndrome MDS 53 gemcitabine Gemzar 53 essential thrombocythemia 53 nerve degeneration 53 thrombolytic agents 53 Myelofibrosis 53 KRAS status 53 Thrombotic events 53 ponatinib 52 Amrubicin 52 platinum refractory 52 histological subtype 52 blastic phase 52 neutropenia dehydration dyspnea 52 viral titers 52 aHUS 52 MYLOTARG 52 SCCHN 52 CytoFabTM 52 PLX cells 52 Omacetaxine 52 estramustine 52 cediranib 52 OHR/AVR# 52 fibrinolytic 52 achieved sustained virological 52 ELACYT 52 platelet reactivity 52 antiangiogenic therapy 52 idarubicin 52 tenecteplase 52 oxypurinol 52 AQ4N 52 multiple myeloma MM 52 papillary renal cell carcinoma 52 severe neutropenia 52 eosinophilic asthma 52 CTEPH 52 follicular lymphoma FL 52 leukemia CLL 52 erythematous 52 imatinib mesylate 52 receptor tyrosine kinase inhibitor 52 motesanib 52 cytotoxic therapies 52 hypomethylating agents 52 GRASPA ® 52 lenalidomide dexamethasone 52 gemcitabine carboplatin 52 fibrin deposition 52 amrubicin 52 refractory cutaneous T 52 Gleevec Glivec 52 atypical hemolytic uremic syndrome 52 invasive candidiasis 52 DMARD 52 Chronic Myeloid Leukemia CML 52 SNT MC# 52 acute HAE attacks 52 atelectasis 52 Rhucin R 52 refractory chronic myeloid 52 cetuximab Erbitux ® 52 potentially hepatotoxic 52 Tasimelteon 52 adenomatous 52 esophageal candidiasis 52 thrombi 52 lumiliximab 52 CR CRu 52 locoregional recurrence 52 immunomodulatory therapy 52 CML CP 52 glomerular filtration 52 lupus nephritis 52 chronic lymphocytic leukemia CLL 52 neutrophilic 52 huC# DM4 52 cervical lymph nodes 52 mapatumumab 52 ischemic complications 52 TKIs 52 Telintra 52 mitomycin C 52 extravasation 52 taxane chemotherapy 52 refractory NSCLC 52 B CLL 52 EGFR expressing 52 non metastatic osteosarcoma 52 taxane resistant 52 oblimersen 52 VFEND 52 gefitinib Iressa 52 Ceflatonin 52 polycythemia vera PV 52 interferon beta therapy 51 imatinib mesylate Gleevec 51 EGFR mutation positive 51 glioblastoma tumors 51 ALK inhibitors 51 superficial bladder cancer 51 hypersensitivity allergic reactions 51 neurocognitive deficits 51 gemifloxacin 51 mTOR inhibitors 51 Doxil ® 51 neoplastic 51 biochemical abnormalities 51 arbaclofen 51 ischemic mitral regurgitation 51 metaglidasen 51 octreotide 51 acute myeloid 51 relapsed ovarian cancer 51 plasma pharmacokinetics 51 target lesion revascularizations 51 stent thromboses 51 trastuzumab Herceptin ® 51 Hodgkin lymphoma NHL 51 hepatic cirrhosis 51 haematological malignancies 51 antiangiogenic drugs 51 adalimumab Humira 51 BNC# 51 CA4P 51 Vorinostat 51 CIMZIA TM 51 Vaprisol 51 antineoplastic 51 ALB # 51 osteogenic 51 EGFR tyrosine kinase inhibitor 51 Triapine R 51 PASI scores 51 Postoperatively 51 anaplastic 51 somatostatin analogues 51 inflammatory cascade 51 PegIFN RBV 51 candidemia 51 relapsed refractory multiple myeloma 51 depression TRD 51 phase IIb trial 51 AGILECT R 51 Natalizumab 51 gastroduodenal 51 MAGE A3 ASCI 51 proliferative diabetic retinopathy 51 VNP#M 51 pegylated liposomal doxorubicin 51 Removab 51 alkylating agents 51 antimetabolite 51 hematological cancers 51 unfavorable cytogenetics 51 Pemetrexed 51 femoral fracture 51 radiographic progression 51 neurologic progression 51 small lymphocytic lymphoma 51 Cimzia TM 51 elacytarabine 51 calcineurin inhibitors 51 immune modulating 51 lymphoid malignancies 51 antiangiogenic activity 51 C1 INH 51 CLL SLL 51 relapsed refractory 51 dasatinib Sprycel 51 complete cytogenetic 51 biliary obstruction 51 intravesical 51 zalutumumab 51 del 5q 51 EGFR HER2 51 Chronic lymphocytic leukemia CLL 51 tipranavir ritonavir 51 radiotherapy RT 51 Rheumatoid Arthritis RA 51 complement inhibitor eculizumab 51 leukemia APL 51 vismodegib 51 myelodysplastic syndromes 51 uric acid lowering 51 caspofungin 51 myelofibrosis 51 metastatic renal cell 51 TELCYTA 50 malignant pleural mesothelioma 50 gemcitabine Gemzar ® 50 acute myeloid leukemia AML 50 CR nPR 50 Torsades de Pointes 50 ganetespib 50 recurrent glioblastoma 50 OncoVEX GM CSF 50 esophageal carcinoma 50 talabostat 50 relapsed multiple myeloma 50 rindopepimut 50 peripheral sensory neuropathy 50 dasatinib Sprycel ® 50 MabThera Rituxan 50 ERK activation 50 ribavirin RBV 50 cannabinor 50 cytoreduction 50 Proxinium TM 50 heavily pretreated 50 haemolytic 50 Cloretazine 50 adriamycin 50 anthracyclines taxanes 50 recurrent malignant glioma 50 remission CR 50 OXi# 50 evaluating Prochymal 50 Xcytrin 50 Complete Response CR 50 myelodysplastic syndromes MDS 50 KIACTA ™ 50 reteplase 50 chemo radiotherapy 50 refractory acute myeloid 50 histologic subtype 50 EDSS scores 50 heavily pretreated patients 50 virologic failure 50 occlusive disease 50 VEGF inhibitors 50 elevated bilirubin 50 metastatic sarcoma 50 Arsenic trioxide 50 Apoptone 50 secondary hyperparathyroidism 50 Pseudomonas aeruginosa infections 50 tophi 50 CytoFab ™ 50 AML acute myeloid 50 relapsed MM 50 Rituxan rituximab 50 hematologic 50 locoregional 50 neutrophil counts 50 CHOP chemotherapy 50 systemic ALCL 50 EGFr 50 refractory Hodgkin 50 relapsed leukemia 50 APTIVUS R 50 jugular venous 50 elotuzumab 50 hematopoietic cancers 50 glufosfamide 50 LHRH agonists 50 certolizumab 50 hematological 50 achieve sustained virologic 50 piperacillin tazobactam 50 Troxatyl 50 painful diabetic neuropathy 50 Fanconi syndrome 50 TTF Therapy 50 neutrophil count 50 efficacy endpoint 50 topotecan 50 Endothelial dysfunction 50 enalapril 50 pharmacodynamic PD 50 hepatitis C genotype 50 intrahepatic 50 CCR5 tropic HIV 50 Chronic Myelogenous Leukemia CML 50 amphotericin B 50 IV NSCLC 50 atypical Hemolytic Uremic Syndrome 50 PNH patients 50 idiopathic thrombocytopenic purpura 50 recurrent NSCLC 50 pouchitis 50 plasma uric acid 50 S/GSK# 50 microtubule targeting 50 PROCHYMAL 50 mRCC 50 NNRTI resistance 50 cMET 50 immune thrombocytopenic purpura 50 NP2 Enkephalin 50 neurological manifestations 50 systolic function 50 Imatinib 50 crizotinib PF # 50 seliciclib 50 Sudhir Agrawal D.Phil 50 Diffuse Large B 50 5FU 50 intimal hyperplasia 50 OMNARIS HFA 50 curative resection 50 lenalidomide Revlimid R 50 factor TNF 50 overlapping toxicities 50 troponins 50 cancer mCRC 50 EGFR expression 50 budesonide foam 50 generalized seizures 50 uridine triacetate 50 Chronic lymphocytic leukemia 50 anti HBc 50 pulmonary inflammation 50 SAR# [004] 50 recurrent genital herpes 50 calcineurin inhibitor 50 locoregional disease 49 osteolytic 49 weekly subcutaneous injections 49 myeloablative 49 phase IIb clinical 49 pediatric malignancies 49 cytotoxic therapy 49 HBsAg 49 anti angiogenic agents 49 imatinib Gleevec ® 49 tyrosine kinase inhibitor 49 Retreatment 49 Alequel 49 TNF alpha inhibitors 49 antiangiogenic agents 49 variant alleles 49 paliperidone ER 49 creatine kinase MB 49 polycythemia vera essential thrombocythemia 49 p# inhibitor 49 CsA 49 rALLy 49 Critical limb ischemia 49 thymic carcinoma 49 GSK3B 49 Histopathologic examination 49 achieving PASI 49 pleurodesis 49 acetonide FA 49 Circulating tumor cells 49 Vicinium TM 49 peritoneal carcinomatosis 49 chronic HCV 49 pancreatic adenocarcinoma 49 microvascular endothelial cells 49 Behcet uveitis 49 tumors GIST 49 cytotoxic chemotherapy 49 radiographic findings 49 IGF 1R inhibitor 49 Helicobacter pylori eradication 49 partial remissions 49 taxane therapy 49 romidepsin 49 Sutent sunitinib 49 pleiotropic 49 arterial calcification 49 metastatic RCC 49 4mg/kg 49 cisplatin chemotherapy 49 neovascular diseases 49 hepatic metastases 49 detectable HCV RNA 49 adecatumumab 49 defibrotide 49 EGFR mutation 49 thalidomide Thalomid 49 PRT# 49 oral prodrug 49 DOXIL 49 rhEPO 49 follicular lymphoma 49 Nexavar sorafenib 49 intratumoral 49 GvHD 49 osteoblastic 49 relapsed ALL 49 investigational monoclonal antibody 49 epithelioid 49 chlorambucil 49 indolent lymphoma 49 Uricase PEG 49 azacitidine 49 liver metastases 49 lymphocytic leukemia 49 tipranavir 49 Pixantrone 49 oral Hycamtin 49 RRMS patients 49 therapeutic regimens 49 thrombus formation 49 acute mania 49 dose limiting toxicities 49 Erlotinib 49 dalteparin 49 symptomatic paroxysmal AF 49 Folotyn 49 inducible ischemia 49 MyVax 49 genotype 1b 49 JAK#/JAK# inhibitor 49 ruxolitinib 49 relapsed acute myelogenous 49 pleural fluid 49 patients evaluable 49 CYT# potent vascular disrupting 49 refractory ovarian cancer 49 pamidronate 49 cetuximab Erbitux 49 PNP inhibitor 49 PSA nadir 49 femoral fractures 49 anti angiogenic drugs 49 Irinotecan 49 receiving VICTRELIS 49 IL#B 49 leukemic cells 49 surgical decompression 49 trans retinoic acid ATRA 49 pCR 49 trabedersen 49 refractory CTCL 49 relapsed CLL 49 virologic response 49 ritonavir boosted 49 TELINTRA 49 interferon IFN 49 biologic therapy 49 lung metastases 49 squamous cell carcinoma SCC 49 glycated hemoglobin levels 49 relapsers 49 acute ischemia 49 TNF inhibitors 49 fluvastatin 49 fallopian tube cancers 49 alvespimycin 49 neuropsychiatric symptoms 49 cetuximab Erbitux R 49 chemotherapeutic regimen 49 plus methotrexate 49 intralesional 49 recurrent GBM 49 pan HDAC inhibitor 49 Lu AA# 49 Aptivus ® 49 Vidaza ® 49 urothelial carcinoma 49 undetectable PSA 49 peritumoral brain edema 49 histologies 49 Hepatocellular Carcinoma HCC 49 clinically meaningful differences 49 Miraxion 49 primary immunodeficiency PI 49 bosutinib 49 HQK 49 antiproliferative 49 mCRC patients 49 concurrent chemoradiation 49 relapsing remitting MS RRMS 49 concomitant AEDs 49 CANCIDAS 49 LHRH analogues 49 gastrointestinal stromal tumors 49 hepatitis C HCV 49 bendamustine 49 basal cell carcinoma BCC 49 lymphoma CTCL 49 SJIA 49 Fibrillex TM 49 HuMax CD4 49 tipranavir r 49 vascular disrupting agent 49 Sezary syndrome 49 prostate carcinoma 49 voriconazole 49 eplerenone 49 liver histology 48 NYHA Class II 48 FOLFIRI 48 sustained virological response 48 FDG uptake 48 SUVmax 48 anti angiogenic therapy 48 venous stasis ulcers 48 catheter occlusion 48 omega interferon 48 vandetanib 48 generalized tonic clonic seizures 48 chronic immune thrombocytopenic 48 liposomal formulation 48 dysrhythmias 48 Pegylated Liposomal Doxorubicin 48 inhaled iloprost 48 FOLFOX6 48 lymphomas leukemias 48 gastrointestinal stromal tumor GIST 48 disease modifying antirheumatic 48 anthracycline therapy 48 Telcyta 48 murine model 48 CYP#A# substrate 48 mitoxantrone plus 48 subependymal giant cell 48 completely resected 48 Phase 2a trial 48 PEG IFN 48 intravenous bisphosphonates 48 mTOR inhibition 48 visceral metastases 48 Phase #/#a trial 48 adjuvant colon cancer 48 venous stasis 48 differentiated thyroid 48 systemic antifungal 48 curability 48 BCG refractory 48 posterior uveitis 48 castration resistant prostate cancer 48 MabCampath 48 Anthracycline 48 RSD# oral 48 tiuxetan 48 LHRH receptor positive 48 maribavir 48 oncologic diseases 48 gastrointestinal stromal tumor 48 bezafibrate 48 refractory chronic lymphocytic 48 Voreloxin 48 cutaneous T 48 SNP rs# [002] 48 venous reflux 48 PEGPH# 48 Nicole Onetto MD 48 virologic 48 HER2 expression 48 Tarceva erlotinib 48 serum HBV DNA 48 proteasome inhibitor 48 Aggrastat ® tirofiban hydrochloride 48 Cytarabine 48 Evoltra TM 48 MLL AF9 48 adefovir 48 bladder carcinoma 48 TBC# 48 stage IIIB 48 hepatocellular cancer 48 urate lowering 48 galiximab 48 dacarbazine DTIC 48 nalbuphine ER 48 small molecule tyrosine 48 serum ALT 48 Lenalidomide 48 azacytidine 48 urocortin 2 48 periprocedural 48 lymphovascular invasion 48 Atiprimod 48 TroVax ® 48 rufinamide 48 seropositive patients 48 rEV# 48 xanthine oxidase inhibitor 48 anthracyclines 48 bleomycin 48 Fludara 48 alefacept 48 metastatic renal cell carcinoma 48 Phase Ib study 48 imexon 48 NRTI 48 ceftazidime 48 purpura ITP 48 peripheral arterial 48 Chronic Lymphocytic Leukemia CLL 48 progression TTP 48 ZOLINZA 48 radical prostatectomy RP 48 BRAF V# mutation 48 mGluR5 NAM 48 Malignant pleural mesothelioma 48 urothelial cancer 48 osteosarcomas 48 papillary 48 Topotecan 48 KRAS mutations occur 48 lymphoma subtypes 48 interstitium 48 baseline LDH 48 coronary plaques 48 OMAPRO 48 standard chemotherapy regimen 48 trabectedin 48 follicular NHL 48 fallopian tube carcinoma 48 achieved sustained virologic 48 Myriad Flurizan 48 Genasense ® 48 Gliadel Wafer 48 IMC A# 48 apremilast 48 biliary strictures 48 CINTREDEKIN BESUDOTOX 48 enzastaurin 48 FOLPI 48 MMP inhibitors 48 coagulation parameters 48 Tasigna prolongs 48 ximelagatran 48 DOXIL ® 48 Doxorubicin 48 colorectal liver metastases 48 epithelialization 48 coinfected patients 48 chronic periodontitis 48 Mitoxantrone 48 Dacogen injection 48 olmesartan 48 anti EGFR antibody 48 plasma renin activity 48 spirometric 48 velafermin 48 anthracycline taxane 48 #mg BID [001] 48 metastatic gastric 48 liposomal doxorubicin 48 tumor shrinkage 48 KRAS wild 48 liver resection 48 refractory metastatic colorectal cancer 48 CCL# 48 ADAGIO study 48 Pharmacokinetics PK 48 Suicidal ideation 48 HBeAg seroconversion 48 Ibritumomab Tiuxetan 48 intravesical therapy 48 prior chemotherapy regimens 48 rituximab refractory 47 etoposide 47 PCa 47 ovarian carcinoma 47 psoriatic 47 Apo2L 47 grade serous ovarian 47 meningeal 47 recurrent DVT 47 Follicular Lymphoma 47 Akt inhibitor 47 evaluable subjects 47 surgical revascularization 47 tracer uptake 47 #D#C# 47 radiochemotherapy 47 huN# DM1 47 nonmetastatic prostate cancer 47 TNF alpha inhibitor 47 MetMAb 47 mesangial 47 EGFR expressing mCRC 47 pulmonary regurgitation 47 Corlux 47 Solid Tumors criteria 47 Benlysta belimumab 47 sunitinib 47 refractory CLL 47 Alemtuzumab 47 abiraterone acetate 47 OvaRex ® MAb 47 glioblastoma multiforme GBM 47 iniparib 47 DMARD therapy 47 achieved ACR# 47 milatuzumab 47 GVAX 47 transplantation HCT 47 Bortezomib 47 refractory prostate cancer 47 Mitomycin C 47 serum IgE 47 ARIKACE ™ 47 Kaplan Meier curve 47 hepatocellular carcinomas 47 phase IIb study 47 unmeasured confounders 47 comparator PI r 47 #mg QD [001] 47 Actinic Keratosis 47 Sorafenib 47 bardoxolone methyl 47 corneal stroma 47 etiologic factors 47 PROSTVAC TM 47 Mipomersen 47 prostate carcinomas 47 Tarceva TM 47 HCV infected 47 ThGRF 47 anti TNF 47 evaluable patients 47 BAY #-# 47 axitinib 47 serum urate 47 TYSABRI natalizumab 47 relapsed SCLC 47 PS# DARA 47 Rezular 47 hereditary deficiency 47 undergone splenectomy 47 irbesartan 47 prodrome 47 PI3K inhibitors 47 deferiprone 47 forodesine 47 mg/m2 cohort 47 metastatic lung cancer 47 tanespimycin 47 antiresorptive 47 Provecta 47 pomalidomide 47 pegfilgrastim 47 decitabine 47 HBeAg negative 47 subclinical disease 47 reticular 47 IRESSA 47 iroxanadine 47 D aspartate NMDA receptor 47 sustained virologic response 47 immunosuppressant 47 receiving highly emetogenic 47 coagulation disorders 47 arsenic trioxide ATO 47 gallium nitrate 47 SVR# 47 IMA# 47 Neovascular AMD 47 colorectal polyp 47 tirofiban 47 HyQ 47 ZACTIMA 47 metastatic bladder 47 imetelstat 47 neuropsychiatric events 47 BLA filing 47 vivo coagulation 47 Tamibarotene 47 thrombosis blood clots 47 liver scarring 47 olaparib 47 metastatic HRPC 47 nodular partial response 47 bevacizumab Avastin ® 47 DLBCL 47 prospectively defined 47 treatment naive genotype 47 squalamine 47 arterial insufficiency 47 peginterferon 47 advanced carcinoid 47 corticosteroids immunoglobulins 47 standard chemotherapy regimens 47 darbepoetin alpha 47 cisplatin gemcitabine 47 severe dermatologic toxicities 47 severe oral mucositis 47 docetaxel Taxotere ® 47 tissue fibrosis 47 HBeAg positive 47 benign prostatic hypertrophy BPH 47 resectable 47 fulvestrant 47 cutaneous T cell 47 acute leukemias 47 pAkt 47 cytotoxic agents 47 Prodarsan ® 47 afatinib 47 cartilage degeneration 47 chemoresistant 47 follicular thyroid cancer 47 urothelial 47 Gattex 47 taxane refractory 47 Ki# 47 neoplasia 47 briakinumab 47 allogeneic stem cell 47 Raynaud phenomenon 47 conventional DMARDs 47 depsipeptide 47 adjuvant radiotherapy 47 enteroviral infection 47 atazanavir ritonavir 47 bone metastasis 46 lymph node enlargement 46 Acute Myelogenous Leukemia AML 46 humanised monoclonal antibody 46 fatty infiltration 46 low dose cytarabine 46 degranulation 46 erlotinib Tarceva ® 46 anticancer activity 46 CYP#C# * 46 neurogenic 46 reintervention 46 HCV RESPOND 2 46 oligodendroglial progenitor cells 46 primidone 46 intra arterial 46 Paraplatin ® carboplatin 46 PLX# 46 TNF inhibitor 46 castrate resistant 46 DMARDS 46 neoadjuvant treatment 46 relapsing remitting multiple sclerosis 46 ARCALYST 46 Archexin 46 melanoma metastases 46 SinuNase TM 46 Cotara 46 IGF IR 46 Darinaparsin 46 dirucotide 46 Panzem R NCD 46 oral vancomycin 46 astrocytoma 46 Mitral regurgitation 46 TORISEL 46 alfa 2a 46 neuropsychiatric adverse 46 TYMS 46 cabazitaxel 46 enteric bacteria